Abstract
The abandonment of need for pulsatile flow in favor of the unnatural physiology of continuous flow circulation with current left ventricular assist systems (LVAS) led to the widespread application of these devices in the patients with advanced heart failure refractory to medical therapy (1). Troublesome consequences, related to hemocompatibility related adverse effects (the clinical consequences of interaction between the device and blood interface) began to surface once long-term support was realized (2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
